$ROK — AVOID 📊 | 6 MONTHS THESIS

$ROK — AVOID 📊 | 6 MONTHS THESIS 🎯 Q1 2026 | Rev $2.2B | EPS $3.30 vs $2.88 🟢 💡 Consensus underestimated Q2 EPS by 14.6%, but the beat is now fully discounted. The market expects continued elevated growth, and the current 38x forward P/E implies high single-digit earnings growth in perpetuity. 📉 Reward/risk: 0.5:1 🏢 Business Quality: 8/10 📊 Valuation: rich – using P/E (46x TTM, 38x forward), EV/Sales (~5.7x estimated), and FCF yield (low single digits), all above peer medians (industrial peers... 🔮 Catalyst: Next earnings report or macro catalyst (e.g., strong PMI data) could provide a catalyst, but timing is beyond 3 months 💰 Entry: $400, stop $370, target $500 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/ROK0617

🎯 Q1 2026 | Rev $2.2B | EPS $3.30 vs $2.88 🟢